NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($1.05). The biopharmaceutical company had revenue of $12.43 million for the quarter, compared to analyst estimates of $13.33 million. View Theravance Biopharma's Earnings History.

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Theravance Biopharma.

4 Wall Street analysts have issued 12 month price targets for Theravance Biopharma's stock. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's stock price to reach $35.75 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

Press coverage about TBPH stock has been trending extremely negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Theravance Biopharma earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Theravance Biopharma.

Theravance Biopharma saw a decline in short interest in December. As of December 31st, there was short interest totalling 2,640,000 shares, a decline of 5.4% from the December 15th total of 2,790,000 shares. Based on an average daily trading volume, of 309,100 shares, the days-to-cover ratio is currently 8.5 days. Currently, 6.9% of the shares of the company are sold short. View Theravance Biopharma's Current Options Chain.

Some companies that are related to Theravance Biopharma include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), GW Pharmaceuticals PLC- (GWPH) and Progenics Pharmaceuticals (PGNX).

Theravance Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

TBPH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

TBPH stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Theravance Biopharma.

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TBPH stock can currently be purchased for approximately $26.19.

Theravance Biopharma has a market capitalization of $1.49 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.

The official website for Theravance Biopharma is http://www.theravance.com/.

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]